ns-089/ncnp-02
Nucleic acidexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 6, 2019 (NCT04129294)
Timeline
Indications
Mechanism of action
- DystrophinSupplementation
DMD supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05996003 | Phase 2 | Aug 10, 2023 | Nippon Shinyaku Co Ltd |
| NCT05135663 | Phase 2 | Jun 23, 2021 | Nippon Shinyaku Co Ltd |
| NCT04129294 | Phase 1/Phase 2 (Phase 2) | Nov 6, 2019 | National Center of Neurology and Psychiatry, Japan, Nippon Shinyaku Co Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nippon Shinyaku Co Ltd | For profit | 3 | 2 | 1 | 2019 |
| National Center of Neurology and Psychiatry, Japan | Government | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1